237 related articles for article (PubMed ID: 27449297)
21. Myeloproliferative disorder in Noonan syndrome.
Bastida P; García-Miñaúr S; Ezquieta B; Dapena JL; Sanchez de Toledo J
J Pediatr Hematol Oncol; 2011 Jan; 33(1):e43-5. PubMed ID: 20829714
[TBL] [Abstract][Full Text] [Related]
22. Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis.
Wang Z; Medrzycki M; Bunting ST; Bunting KD
Oncotarget; 2015 Oct; 6(30):28961-72. PubMed ID: 26338970
[TBL] [Abstract][Full Text] [Related]
23. An essential role of CBL and CBL-B ubiquitin ligases in mammary stem cell maintenance.
Mohapatra B; Zutshi N; An W; Goetz B; Arya P; Bielecki TA; Mushtaq I; Storck MD; Meza JL; Band V; Band H
Development; 2017 Mar; 144(6):1072-1086. PubMed ID: 28100467
[TBL] [Abstract][Full Text] [Related]
24. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
Sakashita K
Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
[TBL] [Abstract][Full Text] [Related]
25. Impaired T-cell development in the absence of Vav1 and Itk.
Raberger J; Boucheron N; Sakaguchi S; Penninger JM; Ellmeier W
Eur J Immunol; 2008 Dec; 38(12):3530-42. PubMed ID: 19009524
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.
Duyvestyn JM; Taylor SJ; Dagger SA; Orandle M; Morse HC; Thien CB; Langdon WY
PLoS One; 2014; 9(4):e94717. PubMed ID: 24718698
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.
Zhang J; Wang J; Liu Y; Sidik H; Young KH; Lodish HF; Fleming MD
Blood; 2009 Feb; 113(6):1304-14. PubMed ID: 19066392
[TBL] [Abstract][Full Text] [Related]
28. CBL-B is required for leukemogenesis mediated by BCR-ABL through negative regulation of bone marrow homing.
Badger-Brown KM; Gillis LC; Bailey ML; Penninger JM; Barber DL
Leukemia; 2013 Apr; 27(5):1146-54. PubMed ID: 23160449
[TBL] [Abstract][Full Text] [Related]
29. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP
J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108
[TBL] [Abstract][Full Text] [Related]
30. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.
Bandi SR; Brandts C; Rensinghoff M; Grundler R; Tickenbrock L; Köhler G; Duyster J; Berdel WE; Müller-Tidow C; Serve H; Sargin B;
Blood; 2009 Nov; 114(19):4197-208. PubMed ID: 19734451
[TBL] [Abstract][Full Text] [Related]
31. A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.
Xu D; Wang S; Yu WM; Chan G; Araki T; Bunting KD; Neel BG; Qu CK
Blood; 2010 Nov; 116(18):3611-21. PubMed ID: 20651068
[TBL] [Abstract][Full Text] [Related]
32. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O
Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879
[TBL] [Abstract][Full Text] [Related]
33. Juvenile myelomonocytic leukemia.
Proytcheva M
Semin Diagn Pathol; 2011 Nov; 28(4):298-303. PubMed ID: 22195407
[TBL] [Abstract][Full Text] [Related]
34. Mice expressing KrasG12D in hematopoietic multipotent progenitor cells develop neonatal myeloid leukemia.
Tarnawsky SP; Kobayashi M; Chan RJ; Yoder MC
J Clin Invest; 2017 Oct; 127(10):3652-3656. PubMed ID: 28846072
[TBL] [Abstract][Full Text] [Related]
35. Myelodysplastic and myeloproliferative disorders of childhood.
Hasle H
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):598-604. PubMed ID: 27913534
[TBL] [Abstract][Full Text] [Related]
36. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
Yoshida N; Doisaki S; Kojima S
Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
[TBL] [Abstract][Full Text] [Related]
37. Ubiquitin Ligases CBL and CBL-B Maintain the Homeostasis and Immune Quiescence of Dendritic Cells.
Tong H; Li X; Zhang J; Gong L; Sun W; Calderon V; Zhang X; Li Y; Gadzinski A; Langdon WY; Reizis B; Zou Y; Gu H
Front Immunol; 2021; 12():757231. PubMed ID: 34630435
[TBL] [Abstract][Full Text] [Related]
38. Juvenile myelomonocytic leukaemia and Noonan syndrome.
Strullu M; Caye A; Lachenaud J; Cassinat B; Gazal S; Fenneteau O; Pouvreau N; Pereira S; Baumann C; Contet A; Sirvent N; Méchinaud F; Guellec I; Adjaoud D; Paillard C; Alberti C; Zenker M; Chomienne C; Bertrand Y; Baruchel A; Verloes A; Cavé H
J Med Genet; 2014 Oct; 51(10):689-97. PubMed ID: 25097206
[TBL] [Abstract][Full Text] [Related]
39. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
[TBL] [Abstract][Full Text] [Related]
40. Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome.
Timeus F; Crescenzio N; Baldassarre G; Doria A; Vallero S; Foglia L; Pagliano S; Rossi C; Silengo MC; Ramenghi U; Fagioli F; Cordero di Montezemolo L; Ferrero GB
Oncol Rep; 2013 Aug; 30(2):553-9. PubMed ID: 23756559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
